Originally published In Press as doi:10.1074/jbc.M207990200 on August 7, 2002
J. Biol. Chem., Vol. 277, Issue 44, 41879-41887, November 1, 2002
Binding of Two Nuclear Complexes to a Novel
Regulatory Element within the Human S100A9 Promoter Drives the
S100A9 Gene Expression*
Claus
Kerkhoff
§¶,
Heiko A.
Hofmann
§**,
Josef
Vormoor
,
Harutyun
Melkonyan§,
Johannes
Roth§,
Clemens
Sorg§, and
Martin
Klempt§
From the § Institute of Experimental Dermatology and the
Department of Pediatric Hematology/Oncology, University of
Muenster, 48149 Muenster, Germany
Received for publication, August 6, 2002
 |
ABSTRACT |
S100A9, also referred to as MRP14, is a
calcium-binding protein whose expression is tightly regulated during
differentiation of myeloid cells. The present study was
performed to study the cell type- and differentiation-specific
transcriptional regulation of the S100A9 gene. Analysis of the S100A9
promoter in MonoMac-6 cells revealed evidence for a novel regulatory
region from position
400 to
374 bp, termed myeloid-related protein
regulatory element (MRE). MRE deletion resulted in a 5.2-fold reduction
of promoter activity. By electrophoretic mobility shift analysis two
nuclear complexes binding to this region were identified and referred to as MRE-binding complex A (MbcA) and MRE-binding complex B (MbcB). By
mutagenesis the MRE-binding motif could be narrowed to a 12-bp region.
The relevance of MRE is deduced from the observations that the
formation of either MRE-binding complex A or MRE-binding complex
B strongly correlated with S100A9 gene expression in a cell
type-specific, activation- and differentiation-dependent manner. Moreover, DNA affinity chromatography and Western blot studies indicate that a Kruppel-related zinc finger protein and the
transcriptional intermediary factor 1
(TIF1
) are involved in an
MRE-binding complex, thereby regulating the S100A9 gene expression.
 |
INTRODUCTION |
Mononuclear phagocytes play a pivotal role in host defense to
pathogens, wound healing, angiogenesis, and various types of chronic
inflammation, e.g. granulomatous reaction, fibrosis, and arteriosclerosis. They originate from hematopoietic precursor cells in
the bone marrow, and their lineage differentiation is coordinated by
the closely regulated expression of cytokines, colony-stimulating
factors, receptors, and transcription factors (for review, see Refs.
1-5). To study lineage differentiation several cell surface antigens,
adhesion molecules (e.g. CD11b, CD18, CD64), and primary
granule proteins (e.g. myeloperoxidase and neutrophil
elastase) have been used as myeloid stage-specific markers. Additional
interesting markers of myeloid differentiation represent the two
myeloid-related proteins MRP8 (S100A8) and MRP14 (S100A9). Studies
using human leukemia models of myelomonocytic development indicate that
S100A8 and S100A9 expression is restricted to a specific stage of
myeloid differentiation. Moreover, their expression is also regulated
in mature blood cells because they are expressed in circulating
neutrophils and monocytes but not in mature tissue macrophages
(6-7).
S100A8 and S100A9 belong to the S100 family of calcium-binding proteins
(for review, see Refs. 8 and 9). Although the exact functions of both
proteins remain unknown, they form heteromeric complexes and bind
polyunsaturated fatty acids in a calcium-dependent manner
(10-13), indicating that the complex may be involved in the intra- and
transcellular arachidonic acid metabolism. They are used as marker
antigens for activated or recruited phagocytes because the first cells
that migrate to inflammatory lesions express S100A8 and S100A9 (7).
These findings together with the presence of enhanced S100A8/A9 levels
in sera from patients suffering from a number of inflammatory disorders
(14-16) have led to the assumption that S100A8 and S100A9 affect
leukocyte trafficking and display a propagating role in inflammatory responses.
The molecular mechanisms underlying the cell type-specific expression
of S100A9 are unknown. The human S100A9 gene has been cloned and
sequenced, and an upstream 1-kb fragment of its promoter was shown to
drive the gene expression in myeloid cells (6). A number of distinct
regulatory regions upstream of the transcription initiation site have
been demonstrated to either activate or repress promoter activity in a
differentiation and tissue/cell-specific manner. For example, two still
unidentified factors were found to bind to the upstream regions
of S100A9 gene during differentiation of HL-60 cells into monocyte-like
cells; one adjacent to the TATA box and another in the region between
400 and
150 (17). Another study revealed a CCAAT/enhancer-binding
protein (C/EBP)1-binding
motif located at position
81 upstream of the S100A9 gene. Both
C/EBP-
and -
bind to this motif in a myeloid/monocytic differentiation-dependent manner (18). C/EBP was shown to
be sufficient alone to drive S100A9 expression in otherwise negative cells. C/EBP up-regulation is antagonized by myb, a
transcription factor active in differentiated myeloid/monocytic cells
(19). The presence of distinct epithelial and myeloid-specific
regulatory regions upstream of the transcription initiation site has
been demonstrated by detailed deletion analysis (20). Besides the very
specific action of particular upstream DNA elements, the S100A9 gene
contains a potent enhancer, which is harbored within positions 153-361
of its first intron (21). The functional relevance of this enhancer in
S100A9 expression is supported by its conservation in human and murine
S100A9 genes at almost identical positions.
The present study was performed to identify regulatory elements within
the human S100A9 promoter that drive the cell type-specific and
differentiation-dependent protein expression. We found a
novel 27-bp region referred to as MRP regulatory element (MRE), which exhibits these characteristics. The functional relevance of this DNA
regulatory region is shown by (i) the binding of two nuclear factors to
the MRE by electrophoretic mobility shift analysis, and (ii) the
finding that the formation of the nuclear protein complexes closely
correlates with the myeloid-specific expression of the S100A9 gene.
Further extensive investigations provide strong evidence that a complex
of a Kruppel-related zinc finger protein and the transcriptional
intermediary factor 1
(TIF1
) are involved in the regulation of
the myeloid-specific S100A9 gene expression.
 |
EXPERIMENTAL PROCEDURES |
Antibodies--
Fluorescein isothiocyanate (FITC)-conjugated
anti-human CD38 (clone T16), phycoerythrin (PE)-conjugated anti-human
CD33 (clone D3HL60.251), and FITC-conjugated anti-human CD15 (clone
80H5) were purchased from Beckman Coulter (Unterschleissheim,
Germany). Allophycocyanin (APC)-conjugated anti-human CD34
(clone 8G12), PE-conjugated anti-human CD11b (clone D12), and
APC-conjugated anti-human CD14 (clone MoP9) were from BD
PharMingen. Biotin-conjugated anti-human S100A9 (clone
S32.2) was from Dianova (Hamburg, Germany). Mouse monoclonal
C/EBP
antibody (H7) was from Santa Cruz Biotechnology, and the
anti-chicken C/EBP
and C/EBP
antibodies were kind gifts of Dr.
Karl-Heinz Klempnauer (Institute of Biochemistry, University of
Muenster, Muenster, Germany). The mouse monoclonal anti-TIF1
antibody was a kind gift of Dr. Pierre Chambon (Institut de
Génétique et de Biologie Moléculaire et Cellulaire
Illkirch, Cedex, France).
Four-color Flow Cytometry--
To investigate S100A9 gene
expression during normal hematopoesis, bone marrow samples obtained to
rule out systemic malignant disease (n = 4), to exclude
bone marrow involvement in patients with non-Hodgkin lymphoma or
sarcoma (n = 3), or to confirm continuous remission
following chemotherapy for acute leukemia (n = 11) were analyzed by four-color flow cytometry. To analyze S100A9 expression at
different stages of myeloid differentiation we used the antibody combinations of anti-CD38-FITC/anti-CD33-PE/anti-S100A9/anti-CD34-APC (immature cells) and
anti-CD15-FITC/anti-CD11b-PE/anti-S100A9/anti-CD14-APC (mature myeloid cells).
Approximately 3-5 × 106 non-separated bone marrow
cells were first incubated for 15 min at room temperature with
saturating amounts of the antibodies binding to myeloid differentiation
markers on the cell surface. Subsequently, the cell membranes were
treated with the Fix & Perm cell permeabilization kit (An-der-Grub,
Kaumberg, Austria) according to the manufacturer's protocol to measure
expression of intracellular S100A9. The cells were then incubated with
biotinylated anti-human S100A9 antibody for 15 min at room temperature
followed by incubation with streptavidin-PerCP. The cells were washed
twice with phosphate buffered saline. Data acquisition and analysis was
performed on a 2-laser (488 and 633 nm) FACSCalibur (BD PharMingen) using CellQuest and Paint-A-Gate-Pro software (BD PharMingen). For time
delay calibration, APC beads (Calibrite APC, BD PharMingen) were
applied according to the manufacturer's instructions. Isotype controls
were included in all analyses.
Cell Culture--
The human monocytic cell line MonoMac-6 (DSM
ACC 124) was cultured in RPMI 1640 medium supplemented with 10% fetal
calf serum, 100 units/ml penicillin/streptomycin, 2 mmol/liter
glutamine, 1% non-essential amino acids, 1 mmol/liter pyruvate, and 9 µg/ml bovine insulin (Sigma). The human histiocytic lymphoma cell
line U937 (ACC 5) was cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. The human B-lymphocytic cell line Raji, the
fibroblast cell line L-132 (ATCC CCL5), and the
keratinocyte cell line HaCaT were cultured in RPMI 1640 medium
supplemented with 10% fetal calf serum, 100 units/ml
penicillin/streptomycin, and 1 mmol/liter glutamine. Human peripheral
blood monocytes and lymphocytes were isolated by Ficoll-Paque and
Percoll density gradient centrifugation (Amersham Biosciences).
Monocytes were cultured in Teflon bags for 1-7 days as described
previously (22). Keratinocyte cultures were grown in serum-free
keratinocyte growth medium (Invitrogen) containing 0.09 mmol/liter
Ca2+ at 37 °C in a humid, 5% CO2 atmosphere.
Construction of Chloramphenicol Acetyltransferase (CAT) Reporter
Plasmids Carrying the S100A9 Promoter--
The 1-kb upstream promoter
fragment of the human S100A9 gene was inserted into the
SmaI/BglII sites of the pCAT3-Basic vector (Promega) containing CAT as a reporter gene to generate pHH1.0T. A
series of 5'-deletion constructs of the S100A9 promoter were prepared
by digestion of pHH1.0T with KpnI and NheI
followed by treatment with exonuclease III at 25 °C for 0.5-10 min,
with subsequent S1-nuclease digestion and self-religation (all enzymes
were from MBI-Fermentas, St. Leon-Rot, Germany). The correct
size of the 5' untranslated region was confirmed by DNA
sequencing. To generate the plasmid pHH400T, the vector pHH1.0T was
digested using the restriction endonuclease SacI. The
construct pHH763T
-400-(
374) was cloned by digestion of the pHH763T
plasmid with SacI and partial digestion with NcoI
to delete the 36 bp of the region from
400 to
364 bp. The herpes
simplex virus thymidine kinase promoter (CLONTECH)
was inserted into the pSP72 vector (Promega) to generate pTKC (21).
Additionally, the region from
400 to
378 bp of the S100A9-promoter
was cloned 5' to the pTKC construct (MRE-pTKC).
Transfections and CAT Assay--
Transfection was performed as
described by Melkonyan et al. (23) with minor modifications.
Nuclear Extraction and Electrophoretic Mobility Shift Assays
(EMSAs)--
Nuclear extracts were prepared essentially as described
(24). For the EMSA reaction, a double-stranded oligonucleotide
encompassing nucleotides
400 to
357 of the S100A9 promoter was
used. The sense oligonucleotide
CAGACCATCCTTGTTGGACTAAAAGGAAGGGGCAGACTGCCATG and its antisense
strand CATGGCAGTCTGCCCCTTCCTTTTAGTCCAACAAGGATGGTCTG were annealed and
end-labeled by thyroxine polynucleotide kinase and
[
-32P]ATP (Hartmann Analytic, Braunschweig, Germany).
EMSAs were performed with nuclear extracts as follows: nuclear protein
(50 µg) was mixed with 3 µg of sheared genomic salmon sperm DNA and
100,000 cpm of the labeled probe (~1 ng) in EMSA buffer (20 mmol/liter Hepes, pH 7.5, 1 mmol/liter MgCl2, 75 mmol/liter
KCl, 1 mmol/liter dithiothreitol, 0.018% (v/v) Nonidet P-40) in a
total volume of 36 µl. In the competition experiments, a 100-fold
molar excess of unlabelled competitor oligonucleotide was added to the
mixture prior to the addition of nuclear protein extracts. This mixture was allowed to incubate for 60 min at 4 °C. Samples were mixed with
12 µl of sample buffer (50% (w/v) sucrose, 0.5 × Tris borate EDTA buffer (where 1 × Tris borate EDTA buffer is 90 mmol/liter Tris borate, 2 mmol/liter EDTA, pH 8.0) and then run on a
non-denaturing 5% polyacrylamide gel in 0.25 × Tris borate EDTA
buffer. The gels were dried and exposed to Kodak XAR-5 x-ray film.
DNA Affinity Chromatography--
The biotinylated MRE
oligonucleotides were synthesized by Applied Biosystems Oligo Factory
(Weiterstadt, Germany). For DNA affinity purification, 0.5-2 mg of
nuclear protein was incubated with 400 pmol double-stranded,
biotinylated MRE oligonucleotide coupled to 500-µg magnetic beads via
streptavidin (Dynal, Hamburg, Germany) and 100 µg of sheared genomic
salmon sperm DNA in 1000 µl of EMSA-buffer. After rotating the
samples for 1 h at 4 °C, the proteins bound to MRE beads were
eluted with EMSA-buffer supplemented with 0, 100, 250, and 1,000 mM NaCl. Aliquots of the different fractions were analyzed
by EMSA and subjected to SDS-PAGE followed by Western blot analysis
using standard protocols.
Northern Blotting--
Total cellular RNA was extracted from
cells by the SDS-citric acid method of Dreier et al. (25).
The Northern blot analysis was performed using standard protocols.
Mass Spectrometry--
After DNA affinity chromatography the 1 M NaCl eluate displaying DNA-binding activity was subjected
to SDS-PAGE, and the proteins were visualized by silver staining. The
proteins were excised from the gel, digested with trypsin, and the
peptide mixtures were extracted from the gel according to Shevchenko
et al. (26) and Zhang et al. (27). Briefly, the
gel slices were shrunk in acetonitrile, dried, and re-swollen in 20 µl of 50 mM NH4HCO3 containing
400 ng of trypsin. Excess trypsin solution was removed, sufficient
buffer was added to cover the gel slices, and digestion was carried out
at 37 °C overnight. Digestion was stopped by adding 5-10 µl of
100% acetic acid, and the supernatant was removed. The gel slices were
extracted twice with 70 µl of acetonitrile, and the supernatants were
pooled and lyophilized. The lyophilized peptides were dissolved in 7 µl of 0.1% aqueous trifluoroacetic acid followed by
hydrophobic chromatography using ZipTips (Millipore, Bedford, MA). The
peptides were eluted with 7 µl of 70% acetonitrile. Samples of 10 mg
of
-cyano were washed with acetone and dissolved in 1 ml of 50/50
(v/v) acetonitrile/ethanol containing 1% of 0.1% aqueous
trifluoroacetic acid. Then, 0.7 µl of this matrix preparation was
spotted onto the target followed by the same volume of sample. Both
solutions were directly mixed on the target. MALDI-mass spectrometry was carried out using a TofSpec-2E instrument (Micromass, Manchester, UK). Digests were run in positive ion reflection mode using a matrix
suppression of 500. Masses were externally calibrated and internally
corrected using either the lock mass option of the instrument or
trypsin autolysis peaks providing m/z values >50 ppm up to m/z 3000. The resulting spectra were
analyzed by homology search using Swissprot and NCBI.
 |
RESULTS AND DISCUSSION |
Expression of S100A9 in Normal Bone Marrow--
The expression of
S100A9 appears to be restricted to a specific stage of myeloid
differentiation because the protein is expressed in circulating
neutrophils and monocytes but not in mature tissue macrophages. In
peripheral blood monocytes its expression is down-regulated during
maturation to macrophages (6, 7). In the past, several investigators
had used various human promyelocytic leukemia cell lines, such as
HL-60, U937, and MonoMac-6 cells, as cellular models to study
differentiation-dependent S100A9 gene expression (6, 18,
28). However, less is known about S100A9 gene expression during the
differentiation of human hematopoietic cells. Therefore, we
investigated S100A9 expression during normal hematopoiesis using
four-color flow cytometry of human bone marrow. Immature cells were
distinguished from more mature myeloid cells by staining for either
CD38, CD33, and CD34 (immature cells) or CD15, CD11b, and CD14 (mature
myeloid cells) that reflect different stages of myeloid
differentiation (29, 30).
Primitive hematopoietic cells express the progenitor antigen CD34 but
lack expression of CD38 or any lineage-specific markers. With
differentiation toward the myeloid lineage, immature progenitor cells
acquire expression of the myeloid antigen CD33 followed by
down-regulation of CD34. As shown in Fig.
1, primitive, uncommitted CD34+CD38
CD33
(data not shown)
and early myeloid CD34+CD33+ progenitor cells
lack expression of S100A9 (Fig. 1, green events, upper
right dot blot). During neutrophil maturation, S100A9 is only
detectable in cells that already express CD15, but S100A9 expression
slightly precedes and then correlates with the up-regulation of CD11b
(Fig. 1, blue cells, lower left and right
dot blots). Mature
CD15+CD16+CD33+ neutrophils are
also S100A9-positive (data not shown). Other lineages, including
CD19+ B-cells, CD3+ T-cells, and glycophorin
A-positive erythroid cells, did not express S100A9 (data not
shown). The acquisition of CD15 (Lewis x antigen) marks the transition
from myeloblasts to promyelocytes and the up-regulation of the
M-integrin CD11b differentiation of promyelocytes to
myelocytes (29). Hence, the expression of S100A9 is first initiated
during maturation of promyelocytes toward myelocytes and then
maintained up to the level of mature neutrophils.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
S100A9 expression during neutrophil and
monocyte development. The two upper plots display
S100A9 expression in immature CD34+ cells (green
and highlighted). CD34+ cells were marked on a
CD34-APC versus side scatter (SSC) plot (not
shown). More mature cells of the granulocyte lineage (blue)
were identified by their light scatter profile (upper left dot
plot). Immature CD34+CD33 cells and
CD34+CD33+ myeloid cells lack expression of
S100A9 (upper right plot). The middle and
lower plots illustrate further granulocyte (blue)
and monocyte (red) development. Cells of the granulocytic
and monocytic lineage were identified by their light scatter profile
(middle left plot). The differential expression of CD11b and
CD15 in both lineages (mo, monocyte lineage, red;
gr, granulocytic lineage, blue) is shown
in the middle right plot. The two lower plots
show acquisition of S100A9 in correlation to CD11b (left
plot) and CD15 (right plot) in both lineages.
|
|
Within the monocytic pathway, up-regulation of CD11b precedes
acquisition of intermediate expression of CD15. The up-regulation of
S100A9 correlates with the expression of CD11b (Fig. 1, red events, lower left blot) and CD14 (data not shown). In
contrast to neutrophil development, in monocytes S100A9 expression
precedes up-regulation of CD15 (Fig. 1, red events,
lower right blot). Thus, during both neutrophil and monocyte
development the up-regulation of S100A9 correlates with the acquisition
of CD11b. However, due to the differential expression of CD15 in both
cell lineages, S100A9 expression precedes acquisition of CD15 in the
monocytic pathway and succeeds CD15 expression during neutrophil
maturation. This flow cytometric characterization shows for the first
time that S100A9 expression is tightly regulated in a differentiation- and lineage-specific manner within the hematopoietic system. Note that
our study clearly indicates that the S100A9 protein also represents a
myeloid stage-specific marker.
Identification of a Novel Regulatory Element within the S100A9
Promoter--
Due to the differentiation- and
lineage-dependent expression of S100A9, we investigated the
transcriptional regulation of the human S100A9 gene. MonoMac-6 cells
were transfected with various S100A9 promoter constructs containing CAT
as a reporter gene. The promoter constructs used in this functional
analysis were a 1-kb fragment from position
1,000 extending to the
transcriptional start side and various deletions of this fragment
generated by exonuclease digestions as described under "Experimental
Procedures." This 1-kb proximal region has been found to be
sufficient to drive lineage-specific expression of the S100A9 gene (6,
21). Therefore, the mean transcriptional activities of the deletion
constructs were normalized to the mean activity of the 1-kb fragment.
As shown in Fig. 2, regions of both
positive and negative regulation were present within the 1-kb fragment.
The construct pHH153T was sufficient to drive S100A9 gene expression in
MonoMac-6 cells, indicating that this region might represent a minimal
promoter. The construct pHH763T had a 1.7-fold increase in CAT activity compared with the basic promoter construct pHH1.0T. Subsequent deletions to position
400 bp (pHH533T, pHH520T, pHH432T, and pHH400T)
only slightly affected the relative transcriptional activity. However,
deletion of the region from
400 to
374 bp (promoter construct
pHH374T) resulted in a remarkable reduction of the relative transcriptional activity compared with pHH763T (5.2-fold).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
CAT reporter gene analysis of the human
S100A9 promoter. Deletion constructs of the S100A9 promoter 5'
flanking region extending from position 1000 to 153 bp fused to the
CAT reporter gene were generated and transfected in MonoMac-6 cells as
described under "Experimental Procedures." A schematic
representation of each CAT reporter construct is shown on the
left. The expression level (rel. CAT activity) of
the basic promoter construct pHH1.0T was set as 100%. The values are
the mean ± S.E. from at least twelve independent
transfections.
|
|
To verify the relevance of this 27-bp region for the transcriptional
regulation of the S100A9 gene, we generated a promoter construct of
pHH763T in which the 27-bp region was deleted. Fortunately, the S100A9
promoter adjacent to the region from
400 to
374 bp contained
upstream and downstream recognition sites of SacI and NcoI. The pHH763T construct was digested with these two
endonucleases as described under "Experimental Procedures," and the
resulting promoter construct pHH763T
-400-(
356) was transiently
transfected into MonoMac-6 cells. The mean activity of the deletion
construct was normalized to the mean activity of the pHH763T construct. The pHH763T
-400-(
356) construct exhibited a relative
transcriptional activity similar to the pHH374T construct (Fig.
3), indicating that the 27-bp region may
represent a strong positive regulatory element. We therefore termed
this region MRP (myeloid-related protein) regulatory element (MRE).

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 3.
CAT reporter gene analysis of the
pHH763T -400-( 356) promoter construct.
The promoter construct pHH763T -400-( 356) was generated as
described under "Experimental Procedures" by deletion from the
pHH763T construct. A schematic representation of some other
CAT reporter deletion construct is shown on the left. The
expression level (rel. CAT activity) of the promoter
construct pHH763T was set as 100%. Results represent a minimum of
three separate experiments, each done in duplicate.
|
|
Two Nuclear Factors Bind to MRE--
Further functional analysis
of the MRE was performed by cloning the MRE adjacent to the
heterologous herpes simplex thymidine kinase promoter (pTKC). The
promoter constructs MRE-pTKC as well as pTKC were transiently
transfected into either MonoMac-6 or U937 cells (Fig.
4). The relative transcriptional activity
of MRE-pTKC was slightly increased in MonoMac-6 compared with pTKC, indicating that MRE does not function as a context-independent enhancer
element.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 4.
Functional analysis of MRE in human myeloid
cell lines. MonoMac-6 and U937 cells were transfected with CAT
expression vectors controlled by either the heterologous thymidine
kinase promoter or an MRE-TK fusion construct
(MRE-pTKC). The median CAT-activity of the pHH1.0T-CAT
construct in the cells was set as 100% (rel. CAT activity),
and the error bars indicate the standard error of the
means.
|
|
In the human monocytic cell line U937 the MRE-pTKC construct resulted
in a strong decrease (7.2-fold) of the relative transcriptional activity compared with pTKC (Fig. 3B). To estimate this
result we performed Northern blot analysis of U937 cells and found that U937 cells did not express S100A9 (data not shown). This result is in
accordance with another study (18). Therefore, we suggested that MRE
behaves as a strong negative regulatory element in S100A9-negative cells.
Next, EMSA was performed to analyze the nuclear proteins binding to the
region from
400 to
357 bp, thereby using nuclear extracts prepared
from MonoMac-6 cells and U937 cells. As shown in Fig.
5, in both nuclear extracts DNA-protein
complexes were formed. The binding of proteins to MRE was specific, as
an excess of non-labeled MRE oligonucleotide efficiently competed with
the labeled probe in complex formation, whereas an unrelated
double-stranded oligonucleotide probe did not compete. However, the
resulting DNA-protein complexes in the nuclear extracts of either
MonoMac-6 or U937 cells showed different electrophoretic mobilities.
The complex exhibiting slower electrophoretic mobility is referred to
as MRE-binding complex A (MbcA) and the other complex as MbcB, respectively.

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 5.
EMSA analysis of nuclear extracts from
MonoMac-6 cells and U937 cells. A gel shift assay with
32P-labeled MRE (44 bp, 400 to 357 bp) was carried out
with 50 µg nuclear proteins prepared from various cells as indicated.
Two DNA/protein complexes were identified and indicated as MbcA and
MbcB (arrows). For competition analysis of MRE binding,
either unlabelled MRE oligonucleotide or a nonspecific oligonucleotide
was added at a 100-fold molar excess to the binding reactions. For
further details see "Experimental Procedures."
|
|
For control, we performed analogous EMSA analysis with nuclear extracts
of human blood monocytes (S100A9-positive) and human blood lymphocytes
(S100A9-negative). The results were very similar for MonoMac-6 cells
and the human blood monocytes, and DNA-protein complexes with similar
electrophoretic mobilities were detected. Incubation of the probe with
nuclear extracts from human blood lymphocytes resulted in the formation
of a complex with a similar electrophoretic mobility to the complex
formed in U937 cells (data not shown). Therefore, we assume a
correlation between S100A9 protein expression and binding of the
different protein complexes to the MRE driving the gene expression
within these cells. Based on our findings, the complex MbcB presumably
drives S100A9 gene expression, whereas MbcA might have a negative
regulatory role.
Characterization of the Protein-binding Sequence in MRE--
To
characterize the binding site of the nuclear proteins, first various
double-stranded DNA probes with overlapping and flanking sequences to
the region from
400 to
357 bp were synthesized and used as cold
competitors in EMSA analysis of nuclear extracts of monocytes. The
results are summarized in Fig. 6. The
competition analysis of MRE binding revealed that most likely the
subregion from
400 to
379 bp upstream of the transcriptional start
side contained the MRE. Similar results were obtained for MbcA with the
nuclear extracts prepared from lymphocytes (data not shown).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 6.
Competition EMSA analysis. A gel shift
assay with 32P-labeled MRE oligonucleotide probe (44 bp,
400 to 357 bp) was carried out with 50 µg nuclear proteins
prepared from blood monocytes in the absence and presence of a 100-fold
molar excess of the various overlapping probes for the 400 to
357-bp region and three mutant oligonucleotides
(ds400-357 (A399C, A397C, C395T, and T393G),
ds400-357 (T386C, G385T, A380C, and A379C), and
ds400-357 (G375T, A373G, G371A, and G369T) as indicated.
Solid line, competition; dashed line, no
competition.
|
|
We then used various mutant oligonucleotides as cold competitors (Fig.
6). The formation of MbcB was specifically competed by two
oligonucleotides exhibiting mutations within either the
400 to
392
or the
376 to
368 region, whereas the double-stranded oligonucleotide exhibiting mutations within the
388 to
379 region did not compete for MbcB. Therefore, we concluded that the 12-bp element (5'-GTTGGACTAAAA-3') was involved in the binding of both nuclear factors.
MRE Complex Formation Is Cell-specific and Activation- and
Differentiation-dependent--
Next, we performed EMSAs
with nuclear extracts from various human cell lines to determine the
cellular distribution and lineage specificity. As shown in Fig.
7, the formation of MbcB was largely restricted to myeloid cell lines as it was only present in MonoMac-6 cells and monocytes. The formation of MbcA was observed in the nuclear
extracts of the B-lymphoid cell line Raji and in non-hematopoietic cells, such as HeLa epithelial carcinoma cell line, L132 fibroblasts, HaCaT cells, and keratinocytes. These data confirm our hypothesis that
the formation of either MbcA or MbcB correlates with S100A9 expression.

View larger version (76K):
[in this window]
[in a new window]
|
Fig. 7.
Cell type specificity of MRE complex
formation. EMSAs using radiolabeled MRE oligonucleotide probe were
performed with nuclear extracts from various human cell lines as
indicated. For further details see "Experimental Procedures."
|
|
Our finding that the formation of both complexes was observed in the
nuclear extract of 7-day-cultured monocytes is of interest because S100A9 gene expression is down-regulated during maturation of
human blood monocytes to macrophages (6, 7). Therefore, we investigated
the time course of MRE complex formation during monocyte
differentiation. Nuclear extracts from monocytes cultured for different
time periods were subjected to EMSA analysis. As seen in Fig.
8, the formation of complex MbcB was
decreased during cultivation, whereas the formation of complex MbcA was
induced at day 3 during the differentiation of monocytes to
macrophage-like cells. In control experiments, we confirmed the
down-regulation of S100A9 mRNA transcripts by Northern blot
analysis (data not shown).

View larger version (57K):
[in this window]
[in a new window]
|
Fig. 8.
Formation of MRE complexes during monocyte
differentiation. EMSAs using radiolabeled MRE oligonucleotides
were performed with nuclear extracts from human blood monocytes that
were cultured for different time periods as indicated. For further
details see "Experimental Procedures."
|
|
Short-term stimulation of monocytes by either the calcium ionophore
A23187 or the phorbolester PMA also resulted in down-regulation of
S100A9 mRNA expression (31, 32). Therefore, nuclear extracts of
human blood monocytes stimulated by either A23187 or PMA were subjected
to EMSA analysis. As shown in Fig. 9, the
formation of MbcB was observed in the nuclear extract prepared from
non-stimulated monocytes, whereas MbcA was found in the nuclear
extracts of both calcium ionophor- and phorbolester-stimulated
monocytes. For control, the nuclear extract of lymphocytes was also
subjected to EMSA analysis. Through Northern blot analysis we
confirmed that short-term incubation with these agents indeed resulted
in down-regulation of S100A9 mRNA transcripts (data not shown). The
changes in EMSA banding patterns observed upon cell stimulation were
not due to de novo protein synthesis as confirmed by the
simultaneous addition of actinomycin D (Fig. 9).

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 9.
Effect of phorbolester and calcium ionophore
on MRE complex formation. Human blood monocytes were prepared and
cultured overnight. Subsequently, cells were stimulated for 1 h
with either 100 nmol/liter PMA or 4 µmol/liter A23187 in the presence
and absence of actinomycin D (25 µg/ml). Cells were then harvested,
and nuclear extracts were prepared and subjected to EMSA analysis using
the radiolabeled MRE oligonucleotide extending from 400 to 357
bp.
|
|
Identification of Proteins Participating in Complex
Formation--
To identify the proteins participating in the complex
formation we performed DNA affinity chromatography. Nuclear extracts of
lymphocytes were subjected to affinity purification employing MRE
oligonucleotides as affinity matrix. Nuclear proteins bound to MRE were
eluted within a stepwise gradient with 0, 100, 250, and 1,000 mM NaCl and then analyzed by EMSA. Exclusively, the proteins of the 1 M NaCl eluate displayed DNA-binding
activity, indicating that they specifically interacted with the probe
(Fig. 10A). This fraction
was then subjected to SDS-PAGE, and the proteins were visualized by
silver staining (Fig. 10B). The most prominent protein band
with an apparent molecular mass of 45 kDa, which was exclusively
detected in the 1 M NaCl eluate, was excised from the gel,
digested with trypsin, and subsequently analyzed by MALDI-TOF mass
spectrometry. The analysis of the obtained spectra by using Swissprot
and NCBI databases indicated that the 45-kDa protein resembled the
human Kruppel-related zinc finger protein ZNF184 (GenBankTM
accession no. GI:1769490). Unfortunately, we did not succeed in
analyzing the amino acid sequence of some peptides by electrospray ionization-mass spectrometry analysis. Therefore, the exact identity of
the zinc finger protein remains unknown. Additional evidence for the
Kruppel-related zinc finger protein in the nuclear complex formation
was given by a detailed computer search using the TRANSFAC Matrix
Table (34). This search indicated that MRE contains the putative
binding site for Kruppel-related zinc finger proteins (data not shown).
Interestingly, this binding site is identical to the motif
identified by the competition studies (Fig. 6).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 10.
Analysis of proteins participating in
complex formation. A, DNA affinity chromatography. Nuclear
proteins (1-2 mg total protein) were prepared from lymphocytes and
subjected to DNA affinity chromatography with the MRE oligonucleotide
(position 400 to 357 bp), which was coupled to magnetic beads via
biotin/streptavidin. Proteins specifically bound to MRE were
eluted with different NaCl concentrations, and 10-µl aliquots (100 µl total) were analyzed by EMSA. B, analysis of the
proteins bound to MRE. Aliquots of the different fractions derived from
DNA affinity chromatography were subjected to SDS-PAGE, and the
proteins were visualized by silver staining. The protein of interest is
indicated by an arrow.
|
|
ZNF184 is a classical (C2H2) zinc finger with 19 highly conserved zinc
finger motifs and a Kruppel-associated box (KRAB) domain at the C
terminus of the protein. Kruppel-like zinc finger proteins, named after
the Drosophila segmentation gene Kruppel (35), form one of
the largest families of transcription factors with a broad expression
pattern. For example, Abrink et al. (36) isolated 42 different cDNA clones for Kruppel-related zinc finger proteins that
were expressed in the human monoblast cell line U937. The Kruppel-like
zinc finger proteins can be divided into several subfamilies based on
the number of zinc finger motifs, sequence homology between the
zinc-fingers, and the presence of specific repressor and activation
domains (37-40). The differential expression of several KRAB
domain-containing zinc finger proteins during myeloid differentiation
suggests that they could be important in this developmental process.
The KRAB domain, originally identified as a 75-amino acid sequence in
numerous Kruppel-type zinc finger proteins, is a potent DNA-binding
transcriptional repressor region that is believed to function through
interaction with the TIF1
(37, 41-43). TIF1
has been identified
as an early response gene for the differentiation of HL-60 cells to
either macrophages or granulocytes, for the differentiation of U937
cells to macrophages, and for the differentiation of polymorphonuclear
leukocytes to macrophages (44). It belongs to the
immediate-early (IE) genes (for review, see Ref. 33).
To further characterize the DNA-binding protein complex we performed
Western blots with the different fractions derived from the DNA
affinity chromatography. We found that a protein with an apparently
molecular mass of 110 kDa was immunodetectable with an antibody
directed against TIF1
in the 1 M NaCl eluate (Fig. 11A). Because TIF1
alone
cannot bind DNA, this result clearly indicates that the nuclear complex
binding to MRE most likely consisted of TIF1
and its DNA-binding
interaction partner Kruppel-like zinc finger protein.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 11.
Western blot analyses with
anti-Tif1 . Aliquots of either different fractions
derived from DNA affinity chromatography (A), of
nuclear extracts of monocytes or various other cell types as indicated
(B and C) were subjected to 12% SDS-PAGE
followed by Western blot analysis with anti-TIF1 . TIF1 was
detected as a protein with an apparent molecular mass of 110 kDa. The
lower molecular mass form of TIF1 is presumably due to a
partial proteolytic digestion.
|
|
TIF1
has also been shown to bind to and act as a cofactor for
C/EBP
(45, 46). However, both competion with an ideal C/EBP
oligonucleotide as well as super shift experiments with antisera to
several C/EBP isoforms excluded the possibility that a C/EBP isoform
represented the DNA-binding factor (data not shown).
To investigate whether TIF1
was involved in S100A9 gene regulation
we extended the Western blot analysis with nuclear extracts of various
human cell lines. As shown in Fig. 11, B and C,
TIF1
was expressed in nuclear extracts of lymphocytes, the
B-lymphoid cell lines Raji and Malme, and in non-hematopoietic cells,
such as HeLa epithelial carcinoma cell line, L132 fibroblasts, and HaCaT cells. TIF1
was also immunodetectable in S100A9-negative myeloid cell lines such as HL-60 and U937. TIF1
was not present in
freshly isolated human blood monocytes. However, its expression was
up-regulated at day 3-5 during differentiation to macrophages. Furthermore, TPA-stimulated monocytes were positive for TIF1
. Thus,
the expression pattern of TIF1
closely correlates with both the
formation of MbcA and S100A9 expression. Therefore, we suggest from our
data that TIF1
is one subunit of the negative regulatory nuclear
complex MbcA.
The S100A9 expression is restricted to a specific stage of myeloid
differentiation. In the present study we give evidence that a nuclear
complex consisting of a Kruppel-related zinc finger protein and TIF1
is involved in S100A9 gene expression in a cell type-specific,
activation-, and differentiation-dependent manner. Members
of the Kruppel-related zinc finger protein family have been shown to
play a pivotal role in myeloid differentiation and development. The
importance of TIF1
is highlighted by the fact that TIF1
is
essential for early embryogenesis (48). Although the physiological
functions of KRAB domain-containing zinc finger proteins are unknown at
present, they appear to play an important role in regulating expression
of specific genes during cell differentiation and development. KRAB
domain-containing zinc finger proteins show a temporally and spatially
regulated expression pattern (Ref. 49 and references therein). The KRAB
domain-containing zinc finger proteins ZNF43 and ZNF91 exhibit
expression that is mainly restricted to lymphoid cells, suggesting
roles as transcriptional regulators specific for lymphoid cell
differentiation (50, 51). Others, such as HPF4, HTF10, and HTF34, are
down-regulated during myeloid differentiation (44). In addition, a
number of KRAB zinc finger proteins are candidate genes for
human diseases based on their chromosomal locations (52, 53). Our
finding that one function of the Kruppel-related zinc finger
protein/TIF1
complex may be to regulate the expression of the
myeloid-specific S100A9 gene represents the first link between these
nuclear factors and the S100 protein family. This study gives first
insight into the molecular mechanism of S100A9 gene regulation.
Nevertheless, we are aware that the exact elucidation of the
DNA/protein complexes will require further intensive investigations.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Simone König (Integrated
Functional Genomics, Muenster, Germany) for the MALDI-TOF mass
spectrometry, Dr. Klaus Schulze-Osthoff and Dr. Karl-Heinz Klempnauer
for critical reading of the manuscript, and Silke Ladeur, Heike Hater,
Annegret Rosemann, and Dieter Wiesmann for excellent technical assistance.
 |
FOOTNOTES |
*
This work was supported in part by grants from the Deutsche
Forschungsgemeinschaft (DFG) Project Kl 723/3-1,3-2 and from
Interdisziplinäres Zentrum für Klinische Forschung (IZKF)
of the University of Muenster Project C15 and C23.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These authors contributed equally to this work.
¶
To whom correspondence should be addressed: Inst. of
Experimental Dermatology, von-Esmarch-Str. 58, 48149 Muenster, Germany. Tel.: 49-251-8356584; Fax: 49-251-8356549; E-Mail:
kerkhoc{at}uni-muenster.de.
**
Present address: MTM Laboratories AG, Im Neuenheimer Feld 583, 69120 Heidelberg, Germany.

Present address: Institut fuer Physiologie und Biochemie der
Ernaehrung, Bundesanstalt fuer Milchforschung, 24121 Kiel, Germany.
Published, JBC Papers in Press, August 7, 2002, DOI 10.1074/jbc.M207990200
 |
ABBREVIATIONS |
The abbreviations used are:
C/EBP, CCAAT/enhancer-binding protein;
CAT, chloramphenicol
acetyltransferase;
EMSA, electrophoretic mobility shift
analysis;
KRAB, Kruppel-associated box;
MRE, MRP regulatory element;
Mbc, MRE-binding complex;
MRP, myeloid-related proteins;
TIF1
, transcriptional intermediary factor 1
;
FITC, fluorescein
isothiocyanate;
PE, phycoerythrin;
APC, allophycocyanin;
TK, thymidine
kinase;
MALDI-TOF, matrix-assisted laser desorption/ionization-time of
flight;
PMA, phorbol 12-myristate 13-acetate.
 |
REFERENCES |
| 1.
|
Ogawa, M.
(1993)
Blood
81,
2844-2853[Abstract/Free Full Text]
|
| 2.
|
Hamilton, J. A.
(1993)
Immunol. Today
14,
18-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Shivdasani, R. A.,
and Orkin, S. H.
(1996)
Blood
87,
4025-4039[Free Full Text]
|
| 4.
|
Lenny, N.,
Westendorf, J. J.,
and Hiebert, S. W.
(1997)
Mol. Biol. Rep.
24,
157-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Valledor, A. F.,
Borras, F. B.,
Cullel-Young, M.,
and Celada, A.
(1998)
J. Leukocyte Biol.
63,
405-417[Abstract]
|
| 6.
|
Lagasse, E.,
and Clerc, R. G.
(1988)
Mol. Cell. Biol.
8,
2402-2410[Abstract/Free Full Text]
|
| 7.
|
Zwadlo, G.,
Bruggen, J.,
Gerhards, G.,
Schlegel, R.,
and Sorg, C.
(1988)
Clin. Exp. Immunol.
72,
510-515[Medline]
[Order article via Infotrieve]
|
| 8.
|
Kligman, D.,
and Hilt, D. C.
(1988)
Trends Biochem. Sci.
13,
437-443[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Kerkhoff, C.,
Klempt, M.,
and Sorg, C.
(1998)
Biochim. Biophys. Acta.
1448,
200-211[Medline]
[Order article via Infotrieve]
|
| 10.
|
Siegenthaler, G.,
Roulin, K.,
Chatellard-Gruaz, D.,
Hotz, R.,
Saurat, J. H.,
Hellman, U.,
and Hagens, G.
(1997)
J. Biol. Chem.
272,
9371-9377[Abstract/Free Full Text]
|
| 11.
|
Klempt, M.,
Melkonyan, H.,
Nacken, W.,
Wiesmann, D.,
Holtkemper, U.,
and Sorg, C.
(1997)
FEBS Lett.
408,
81-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Kerkhoff, C.,
Klempt, M.,
Kaever, V.,
and Sorg, C.
(1999)
J. Biol. Chem.
274,
32672-32679[Abstract/Free Full Text]
|
| 13.
|
Kerkhoff, C.,
Sorg, C.,
Tandon, N. N.,
and Nacken, W.
(2001)
Biochemistry
40,
241-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Roth, J.,
Teigelkamp, S.,
Wilke, M.,
Grun, L.,
Tummler, B.,
and Sorg, C.
(1992)
Immunobiology
186,
304-314[Medline]
[Order article via Infotrieve]
|
| 15.
|
Goebeler, M.,
Roth, J.,
Burwinkel, F.,
Vollmer, E.,
Bocker, W.,
and Sorg, C.
(1994)
Transplantation
58,
355-361[Medline]
[Order article via Infotrieve]
|
| 16.
|
Brun, J. G.,
Jonsson, R.,
and Haga, H. J.
(1994)
J. Rheumatol.
21,
733-738[Medline]
[Order article via Infotrieve]
|
| 17.
|
Kuwayama, A.,
Kuruto, R.,
Horie, N.,
Takeishi, K.,
and Nozawa, R.
(1993)
Blood
81,
3116-3121[Abstract/Free Full Text]
|
| 18.
|
Kuruto-Niwa, R.,
Nakamura, M.,
Takeishi, K.,
and Nozawa, R.
(1998)
Cell Struct. Funct.
23,
109-118[Medline]
[Order article via Infotrieve]
|
| 19.
|
Klempt, M.,
Melkonyan, H.,
Hofmann, H. A.,
Eue, I.,
and Sorg, C.
(1998)
Immunobiology
199,
148-151[Medline]
[Order article via Infotrieve]
|
| 20.
|
Klempt, M.,
Melkonyan, H.,
Hofmann, H. A.,
and Sorg, C.
(1999)
J. Cell. Biochem.
73,
49-55[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Melkonyan, H.,
Hofmann, H. A.,
Nacken, W.,
Sorg, C.,
and Klempt, M.
(1998)
J. Biol. Chem.
273,
27026-27032[Abstract/Free Full Text]
|
| 22.
|
Mueller, G.,
Kerkhoff, C.,
Hankowitz, J.,
Pataki, M.,
Kovacs, E.,
Lackner, K. J.,
and Schmitz, G.
(1993)
Arterioscler. Thromb.
13,
1317-1326[Abstract/Free Full Text]
|
| 23.
|
Melkonyan, H.,
Sorg, C.,
and Klempt, M.
(1996)
Nucleic Acids Res.
24,
4356-4357[Abstract/Free Full Text]
|
| 24.
|
Ciotti, P.,
Van Dyke, M. W.,
Bianchi-Scarra, G.,
and Musso, M.
(2001)
Eur. J. Biochem.
268,
225-234[Medline]
[Order article via Infotrieve]
|
| 25.
|
Dreier, J.,
Högger, P.,
and Sorg, C.
(1998)
DNA Cell Biol.
17,
321-323[Medline]
[Order article via Infotrieve]
|
| 26.
|
Shevchenko, A.,
Wilm, M.,
Vorm, O.,
and Mann, M.
(1996)
Anal. Chem.
68,
850-858[Medline]
[Order article via Infotrieve]
|
| 27.
|
Zhang, X.,
Herring, C. J.,
Romano, P. R.,
Szczepanowska, J.,
Brzeska, H.,
Hinnebusch, A. G.,
and Qin, J.
(1998)
Anal. Chem.
70,
2050-2059[Medline]
[Order article via Infotrieve]
|
| 28.
|
van Roozendaal, K. E.,
Darling, D.,
and Farzaneh, F.
(1990)
Exp. Cell Res.
190,
137-140[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Terstappen, L. W.,
Safford, M.,
and Loken, M. R.
(1990)
Leukemia
4,
657-663[Medline]
[Order article via Infotrieve]
|
| 30.
|
Terstappen, L. W.,
Buescher, S.,
Nguyen, M.,
and Reading, C.
(1992)
Leukemia
6,
1001-1010[Medline]
[Order article via Infotrieve]
|
| 31.
|
Roth, J.,
Goebeler, M.,
Wrocklage, V.,
van den Bos, C.,
and Sorg, C.
(1994)
Biochem. J.
301,
655-660[Medline]
[Order article via Infotrieve]
|
| 32.
|
Rammes, A.,
Roth, J.,
Goebeler, M.,
Klempt, M.,
Hartmann, M.,
and Sorg, C.
(1997)
J. Biol. Chem.
272,
9496-9502[Abstract/Free Full Text]
|
| 33.
|
Bravo, R.
(1990)
Cell Growth & Differ.
1,
305-309[Medline]
[Order article via Infotrieve]
|
| 34.
|
Wingender, E.,
Kel, A. E.,
Kel, O. V.,
Karas, H.,
Heinemeyer, T.,
Dietze, P.,
Knuppel, R.,
Romaschenko, A. G.,
and Kolchanov, N. A.
(1997)
Nucleic Acids Res.
25,
265-268[Abstract/Free Full Text]
|
| 35.
|
Preiss, A.,
Rosenberg, U. B.,
Kienlin, A.,
Seifert, E.,
and Jackle, H.
(1985)
Nature
313,
27-32[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Abrink, M.,
Aveskogh, M.,
and Hellman, L.
(1995)
DNA Cell Biol.
14,
125-136[Medline]
[Order article via Infotrieve]
|
| 37.
|
Agata, Y.,
Matsuda, E.,
and Shimizu, A.
(1999)
J. Biol. Chem.
274,
16412-16422[Abstract/Free Full Text]
|
| 38.
|
Peng, H.,
Begg, G. E.,
Harper, S. L.,
Friedman, J. R.,
Speicher, D. W.,
and Rauscher, F. J. I.
(2000)
J. Biol. Chem.
275,
18000-18010[Abstract/Free Full Text]
|
| 39.
|
Poncelet, D. A.,
Bellefroid, E. J.,
Bastiaens, P. V.,
Demoitie, M. A.,
Marine, J. C.,
Pendeville, H.,
Alami, Y.,
Devos, N.,
Lecocq, P.,
Ogawa, T.,
Muller, M.,
and Martial, J. A.
(1998)
DNA Cell Biol.
17,
931-943[Medline]
[Order article via Infotrieve]
|
| 40.
|
Williams, A. J.,
Khachigian, L. M.,
Shows, T.,
and Collins, T.
(1995)
J. Biol. Chem.
270,
22143-22152[Abstract/Free Full Text]
|
| 41.
|
Friedman, J. R.,
Fredericks, W. J.,
Jensen, D. E.,
Speicher, D. W.,
Huang, X. P.,
Neilson, E. G.,
and Rauscher, F. J., III.
(1996)
Genes Dev.
10,
2067-2078[Abstract/Free Full Text]
|
| 42.
|
Moosmann, P.,
Georgiev, O., Le,
Douarin, B.,
Bourquin, J. P.,
and Schaffner, W.
(1996)
Nucleic Acids Res.
24,
4859-4867[Abstract/Free Full Text]
|
| 43.
|
Abrink, M.,
Ortiz, J. A.,
Mark, C.,
Sanchez, C.,
Looman, C.,
Hellman, L.,
Chambon, P.,
and Losson, R.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
1422-1426[Abstract/Free Full Text]
|
| 44.
|
Bellefroid, E. J.,
Poncelet, D. A.,
Lecocq, P. J.,
Revelant, O.,
and Martial, J. A.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
3608-3612[Abstract/Free Full Text]
|
| 45.
|
Natsuka, S.,
Akira, S.,
Nishio, Y.,
Hashimoto, S.,
Sugita, T.,
Isshiki, H.,
and Kishimoto, T.
(1992)
Blood
79,
460-466[Abstract/Free Full Text]
|
| 46.
|
Chang, C. J.,
Chen, Y. L.,
and Lee, S. C.
(1998)
Mol. Cell. Biol.
18,
5880-5887[Abstract/Free Full Text]
|
| 47.
| Deleted in proof
|
| 48.
|
Cammas, F.,
Mark, M.,
Dolle, P.,
Dierich, A.,
Chambon, P.,
and Losson, R.
(2000)
Development
127,
2955-2963[Abstract]
|
| 49.
|
Mark, C.,
Abrink, M.,
and Hellman, L.
(1999)
DNA Cell Biol.
18,
391-396
|
| 50.
|
Bellefroid, E. J.,
Marine, J. C.,
Ried, T.,
Lecocq, P. J.,
Riviere, M.,
Amemiya, C.,
Poncelet, D. A.,
Coulie, P. G.,
de Jong, P.,
and Szpirer, C.
(1993)
EMBO J.
12,
1363-1374[Medline]
[Order article via Infotrieve]
|
| 51.
|
Lovering, R.,
and Trowsdale, J.
(1991)
Nucleic Acids Res.
19,
2921-2928[Abstract/Free Full Text]
|
| 52.
|
Tommerup, N.,
Aagaard, L.,
Lund, C. L.,
Boel, E.,
Baxendale, S.,
Bates, G. P.,
Lehrach, H.,
and Vissing, H.
(1993)
Hum. Mol. Genet.
2,
1571-1575[Abstract/Free Full Text]
|
| 53.
|
Crew, A. J.,
Clark, J.,
Fisher, C.,
Gill, S.,
Grimer, R.,
Chand, A.,
Shipley, J.,
Gusterson, B. A.,
and Cooper, C. S.
(1995)
EMBO J.
14,
2333-2340[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles: